Risk management of mesalazine induced renal failure

Dr Claire Wratten
ByDr Claire Wratten
Published06 March 2020
The MDU has noticed an increase in notification of claims related to renal impairment alleged to be secondary to mesalazine prescribed for inflammatory bowel disease.
ad label

Risk management of mesalazine induced renal failure banner ad 1

This page was correct at publication on 06/03/2020. Any guidance is intended as general guidance for members only. If you are a member and need specific advice relating to your own circumstances, please contact one of our advisers.

Dr Claire Wratten

Dr Claire Wratten is a senior medical claims handler and claims team manager, who joined the MDU in 2006 from a background in nephrology and general medicine.

Risk management of mesalazine induced renal failure